[ad_1]
Vaccine doses for Europe are manufactured at Biontech’s production facilities in Germany and at Pfizer’s plant in Puurs, Belgium. The efficacy of the new crown mutations is currently being investigated.
Following the conditional approval of its corona vaccine in the European Union, the German company Biontech and the US pharmaceutical giant Pfizer want to immediately begin the first deliveries of the preparation to EU member states. “Deliveries will start immediately and will take place gradually over the course of 2020 and 2021 to ensure a fair distribution of vaccines in accordance with the terms of the contract in the EU,” the companies announced Monday night.
Vaccine doses for Europe are said to be manufactured at Biontech’s production facilities in Germany and at Pfizer’s plant in Puurs, Belgium. “Today’s conditional market approval by the European Commission is a historic achievement,” said Biontech chief and co-founder Ugur Sahin. The vaccine was the first to be tested and approved in a large study in more than 44,000 subjects in less than a year. “This great achievement is based on decades of work by many scientists around the world and is also proof of our successful collaboration with our partner Pfizer,” said Sahin.
“Reduce hospital treatments”
“We believe that vaccination can help reduce the number of people in the high-risk population who are hospitalized,” he added. Biontech and Pfizer would collect more efficacy and safety data over the next two years and “test the vaccine for new mutations that emerge.”
According to Biontech, the vaccine is marketed in the EU under the name Comirnaty. The name combines the words Covid-19, mRNA (name of the messenger molecule), Community (community in English) and “Immunity” (immunity). With the name, the company wants to highlight the first approval of a vaccine based on messenger RNA (mRNA). Furthermore, the name should underscore the joint efforts that this approval would now have made possible.
(WHAT)
